chronic spontaneous urticaria

Sanofi, Regeneron to seek FDA nod for Dupixent in hives disorder

Sanofi and Regeneron have presented data from a trial that could help push Dupixent across the FDA finish line to treat chronic spontaneous urticaria.

Kevin Dunleavy Sep 11, 2024 1:00am

After FDA says no on Dupixent for hives disorder, Japan says yes

Feb 16, 2024 10:54am

FDA rejects Sanofi, Regeneron's Dupixent to treat hives disorder

Oct 23, 2023 10:38am

Novartis targets new fields—and CAR-T—for immunology growth

May 10, 2023 5:00pm

Sanofi's Dupixent comes up short, stops hives trial

Feb 18, 2022 10:35am

Sanofi, Regeneron aim Dupixent toward 5 new approvals—and $11B

Jun 11, 2020 10:20am